A number of research firms have changed their ratings and price targets for Quidel (NASDAQ: QDEL):

  • 9/22/2018 – Quidel was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 9/11/2018 – Quidel was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 9/10/2018 – Quidel had its price target raised by analysts at Canaccord Genuity from $78.00 to $80.00. They now have a “buy” rating on the stock.
  • 9/5/2018 – Quidel was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 8/25/2018 – Quidel was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 8/15/2018 – Quidel was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 8/14/2018 – Quidel was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $80.00 price target on the stock. According to Zacks, “Quidel Corp. discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women’s health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis. “
  • 8/14/2018 – Quidel had its price target raised by analysts at Canaccord Genuity from $75.00 to $78.00. They now have a “buy” rating on the stock.
  • 8/8/2018 – Quidel had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $74.00 price target on the stock.
  • 8/8/2018 – Quidel was downgraded by analysts at TheStreet from a “b” rating to a “c+” rating.
  • 8/8/2018 – Quidel had its price target raised by analysts at Craig Hallum from $64.00 to $80.00. They now have a “buy” rating on the stock.
  • 8/6/2018 – Quidel had its price target raised by analysts at Barclays PLC from $65.00 to $78.00. They now have an “overweight” rating on the stock.

Shares of NASDAQ:QDEL traded up $0.13 during trading hours on Tuesday, hitting $64.30. 267,437 shares of the company’s stock traded hands, compared to its average volume of 325,700. Quidel Co. has a 52 week low of $33.01 and a 52 week high of $77.63. The company has a current ratio of 1.10, a quick ratio of 0.71 and a debt-to-equity ratio of 0.22. The firm has a market cap of $2.53 billion, a price-to-earnings ratio of -918.57, a price-to-earnings-growth ratio of 1.03 and a beta of 0.98.

Quidel (NASDAQ:QDEL) last posted its quarterly earnings data on Tuesday, August 7th. The company reported $0.36 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.12. Quidel had a net margin of 4.63% and a return on equity of 19.39%. The company had revenue of $103.16 million during the quarter, compared to analyst estimates of $102.15 million. research analysts forecast that Quidel Co. will post 2.51 earnings per share for the current year.

In other news, VP Edward Keith Russell sold 10,000 shares of the firm’s stock in a transaction dated Thursday, July 12th. The shares were sold at an average price of $68.09, for a total transaction of $680,900.00. Following the completion of the transaction, the vice president now owns 18,887 shares in the company, valued at approximately $1,286,015.83. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Charles P. Slacik sold 1,000 shares of the firm’s stock in a transaction dated Friday, August 10th. The shares were sold at an average price of $68.28, for a total transaction of $68,280.00. Following the transaction, the director now owns 7,820 shares of the company’s stock, valued at approximately $533,949.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 213,200 shares of company stock valued at $14,705,978. Insiders own 16.70% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Great West Life Assurance Co. Can boosted its holdings in shares of Quidel by 55.8% in the second quarter. Great West Life Assurance Co. Can now owns 3,405 shares of the company’s stock worth $227,000 after buying an additional 1,220 shares during the period. MetLife Investment Advisors LLC boosted its holdings in shares of Quidel by 8.8% in the second quarter. MetLife Investment Advisors LLC now owns 15,132 shares of the company’s stock worth $1,006,000 after buying an additional 1,229 shares during the period. Metropolitan Life Insurance Co. NY boosted its holdings in shares of Quidel by 15.9% in the second quarter. Metropolitan Life Insurance Co. NY now owns 10,686 shares of the company’s stock worth $711,000 after buying an additional 1,466 shares during the period. Swiss National Bank boosted its holdings in shares of Quidel by 4.0% in the second quarter. Swiss National Bank now owns 51,600 shares of the company’s stock worth $3,431,000 after buying an additional 2,000 shares during the period. Finally, Gardner Lewis Asset Management L P boosted its holdings in shares of Quidel by 3.1% in the second quarter. Gardner Lewis Asset Management L P now owns 78,425 shares of the company’s stock worth $5,215,000 after buying an additional 2,345 shares during the period. Institutional investors own 88.44% of the company’s stock.

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.

Featured Article: Technical Analysis of Stocks, How Can It Help

Receive News & Ratings for Quidel Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Co and related companies with MarketBeat.com's FREE daily email newsletter.